FOCALIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FOCALIN (FOCALIN).
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
| Metabolism | Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite d-ritalinic acid. Hepatic CYP2D6 plays a minor role. |
| Excretion | Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible |
| Half-life | 2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect |
| Protein binding | 90-95% (primarily to albumin) |
| Volume of Distribution | 2.65 L/kg (extensive tissue distribution; crosses blood-brain barrier readily) |
| Bioavailability | Oral immediate-release: 30-40% (due to first-pass metabolism); Extended-release: approximately 30% |
| Onset of Action | Immediate-release: 20-30 min (oral). Extended-release: 30-60 min (oral). Inhaled: not available |
| Duration of Action | Immediate-release: 3-5 hours (attention deficit hyperactivity disorder symptom control). Extended-release: 8-12 hours (smooth symptom control with once-daily dosing) |
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended. |
| Pediatric use | Age 6-17: initial 2.5 mg twice daily, increase weekly by 2.5-5 mg/day; max 20 mg twice daily or 1 mg/kg/day (whichever less). |
| Geriatric use | Initiate at lowest dose, titrate cautiously; monitor for hypertension and cardiovascular effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FOCALIN (FOCALIN).
| Breastfeeding | Excretion into human milk unknown; however, methylphenidate is present in milk. M/P ratio not available. Potential for adverse effects in nursing infant, including insomnia, decreased appetite, and growth retardation. Alternate feeding method recommended during therapy. |
| Teratogenic Risk | Pregnancy Category C: First trimester - Inadequate human data; animal studies show increased fetal resorptions and malformations at high doses. Second and third trimesters - Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia). Avoid use unless potential benefit outweighs risk. |
■ FDA Black Box Warning
FOCALIN has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Patients should be assessed for risk of abuse before and during therapy.
| Serious Effects |
["Hypersensitivity to dexmethylphenidate or any component of the formulation","Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation","Glaucoma","Severe anxiety, tension, or agitation","Motor tics or family history or diagnosis of Tourette's syndrome"]
| Precautions | ["Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems.","Blood pressure and heart rate increases, psychiatric adverse events (e.g., exacerbation of pre-existing psychosis, mania, aggression), long-term growth suppression in children, seizures, priapism, peripheral vasculopathy including Raynaud's phenomenon."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Fetal surveillance includes ultrasound for growth restriction and signs of distress. Neonatal monitoring for withdrawal symptoms, including irritability, jitteriness, and feeding difficulties. |
| Fertility Effects | No human data on fertility. Animal studies with methylphenidate (active enantiomer) showed reduced fertility in male rats at high doses. Clinical relevance unknown; potential for reversible impairment of spermatogenesis. |